24/7 Market News Snapshot 03 March, 2025 – Aclarion, Inc. Common Stock (NASDAQ:ACON)

March 3, 2025

DENVER, Colo., 03 March, 2025 (247marketnews.com) – (NASDAQ:ACON) are discussed in this article.
Aclarion, Inc. is experiencing an impressive surge in its stock market performance, with shares rising to $5.395, marking a 61% increase from its previous close of $3.350 during pre-market trading. This remarkable trend is supported by a substantial trading volume of 2.10 million shares, suggesting heightened investor interest and confidence in the company’s prospects. Analysts indicate that this bullish momentum may persist, with resistance levels still untested, creating a promising environment for investors seeking opportunities in the evolving landscape of Aclarion.

In parallel to its stock market activities, Aclarion has announced a pivotal commercial agreement with Scripps Health aimed at enhancing chronic low back pain diagnostics. This collaboration facilitates the deployment of Nociscan, an innovative technology harnessing Magnetic Resonance Spectroscopy (MRS) and augmented intelligence to revolutionize the diagnostic process for chronic low back pain. Given the substantial number of individuals affected by this condition, the partnership is poised to broaden access to advanced diagnostic techniques for both patients and leading spine specialists.

Nociscan uniquely quantifies chemical biomarkers associated with lumbar disc pain, enabling a clearer distinction between painful and non-painful discs. This capability provides critical insights for physicians, which are essential for optimizing treatment approaches. Dr. Robert Eastlack, an Orthopedic Surgeon at Scripps Health, underscored the importance of integrating Nociscan into clinical practice, stating its potential to enhance treatment decision-making.

Aclarion’s Chief Strategy Officer, Ryan Bond, articulated the significance of this partnership, noting the commitment to making innovative diagnostic tools widely accessible. As Aclarion advances its mission to tackle the global challenge of chronic low back pain, the introduction of Nociscan at Scripps Health exemplifies a transformative step towards improved patient outcomes and a brighter future for spine care.

Related news for (ACON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.